SRDX News and Press, Surmodics Inc. From 11/11/22

35-subject SWING Trial evaluates the safety, efficacy of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today...

Surmodics press release ( NASDAQ: SRDX ): Q4 Non-GAAP EPS of -$0.26 beats by $0.19 . Revenue of $26M (+16.6% Y/Y) beats by $1.91M . Fiscal Year 2022 Financial Summary Total Revenue of $100.0 million vs $98.05M Consensus a decrease of 5% year-over-year...

Surmodics press release ( NASDAQ: SRDX ): Q4 Non-GAAP EPS of -$0.26 beats by $0.19 . Revenue of $25.99M (+8.4% Y/Y) beats by $1.9M . Guidance: Surmodics expects fiscal year 2023 total revenue to range from $103 million to $107 million, representing an increase ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2022, and introduced its financial outlook for the fiscal yea...

SurVeil™ Drug Coated Balloon (DCB) demonstrates sustained durability of safety, efficacy endpoints SurVeil™ DCB non-inferior to market leading IN.PACT ® Admiral ® DCB at a substantially lower drug dose Surmodics, Inc. (NASDAQ:S...

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter and fiscal year 2022 financial results...

Dr. Kenneth Rosenfield to share study results during Nov. 1 late-breaking trial session Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 24-month data from its TRANSCEND...

Surmodics ( NASDAQ: SRDX ) has entered into a new, five-year credit agreement with MidCap Financial, comprised of up to $100M in term loans and a $25M revolving credit facility. The Company drew $25M on the term loan and $5M on the revolving credit facility at close. T...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a new, five-year credit agreement with MidCap Financial (“MidCap”), comprised of up to $100 millio...

Sundance™ Sirolimus DCB demonstrates lowest binary restenosis at 6 months compared to relevant BTK clinical trials E xcellent safety profile observed with no major amputations and low rates of MAE Surmodics, Inc. (NASDAQ:SRDX), a leading provider of me...